Abivax: Nine Scientific Presentations on Obefazimod at DDW Congress 2026
Abivax announces the presentation of nine scientific abstracts focused on obefazimod at the Digestive Disease Week conference, scheduled from May 2 to 5, 2026, in Chicago. These presentations will cover efficacy, safety, and patient-reported outcomes from the Phase 3 ABTECT program, as well as preclinical models of antifibrotic activity.
The nine abstracts will highlight the results from the Phase 3 ABTECT program concerning obefazimod, Abivax's drug candidate for the treatment of moderately to severely active ulcerative colitis. The presentations will cover efficacy, safety, and patient-reported outcomes, including histological, endoscopic data, and data related to fatigue and quality of life. Preclinical data on antifibrotic activity in two fibrosis models will also be presented.
Confidence in Obefazimod as a Therapeutic Breakthrough
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
According to Fabio Cataldi, Medical Director at Abivax, the data reinforce confidence in the potential of obefazimod as a therapeutic breakthrough for patients with ulcerative colitis, covering the spectrum of disease severity and various treatment lines. Marc de Garidel, CEO of Abivax, emphasizes that the increasing depth of the data set on obefazimod in inflammatory bowel diseases contributes to a better understanding of its potential.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
